Table 2.
Patient Demographics at the Time of Transplant (N=23)
| Age, y | 10.4 (3–13.8) |
| Male sex | 10 (43.5) |
| Prior CHD surgery | 16 (69.6) |
| Indication for listing | |
| Failed repair of CHD | 13 (56.5) |
| Anthracycline induced cardiomyopathy | 5 (21.7) |
| CHD deemed too high risk for repair | 2 (8.7) |
| Dilated cardiomyopathy | 2 (8.7) |
| Lymphocytic myocarditis | 1 (4.3) |
| Support at transplant | |
| Ventilator | 3 (13) |
| ECMO | 0 (0) |
| Inotropes | 12 (52.2) |
| Inhaled nitric oxide | 2 (8.7) |
| Prostacyclin | 1 (4.3) |
| Ventricular assist device | 9 (39.1) |
| Donor ischemic time, h | 3.6 (2.9–4.2) |
| Donor‐to‐recipient weight ratio | 1.3 (1.1–1.6) |
| Required ECMO posttransplant | 1 (4.3) |
| Required dialysis posttransplant | 1 (4.3) |
| Survived to hospital discharge | 23 (100) |
| Posttransplant length of stay, d | 22 (13–32) |
| Maintenance steroids | 17 (73.9) |
| Maintenance immunosuppression at discharge | |
| Tacrolimus/mycophenolate | 12 (54.5) |
| Cyclosporine/azathioprine | 6 (27.3) |
| Cyclosporine/mycophenolate | 2 (9.1) |
| Tacrolimus monotherapy | 1 (4.5) |
| Sirolimus/mycophenolate | 1 (4.5) |
Data are reported as frequency (percentage) for categorical and median (interquartile range) for continuous variables. CHD indicates congenital heart disease, and ECMO, extracorporeal membrane oxygenation.